BCRX - BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance | Benzinga
Monday, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a first-quarter earnings loss of $(0.17) per share versus the consensus estimate loss of $(0.21) per share and $(0.28) reported a year ago.
BioCryst Pharma reported sales of $92.8 million, beating the consensus of $85.61 million. The sales increased 34.9% Y/Y, primarily due to $88.9 million in Orladeyo’s net revenue in the first quarter of 2024, up 30% Y/Y.
“We are off to a fantastic start to the year with outstanding Orladeyo revenue growth and our prioritized pipeline programs advancing on schedule. We are focused on continuing this momentum as we see strong patient demand ...